ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the development and commercialization of innovative medicines targeting central nervous system (CNS) disorders and rare diseases. The company's commercial portfolio includes NUPLAZID, the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis, and DAYBUE, a groundbreaking therapy for Rett Syndrome. ACADIA's robust pipeline demonstrates a strategic focus on addressing significant unmet medical needs within neurology. Key pipeline candidates are advancing through clinical development for conditions such as schizophrenia, Prader-Willi syndrome, Alzheimer's disease psychosis, Lewy Body Dementia with psychosis, essential tremor, treatment-resistant depression, Fragile X syndrome, and other rare genetic neurodevelopmental diseases. The company leverages strategic partnerships, including agreements with Neuren Pharmaceuticals Limited for trofinetide and Stoke Therapeutics, Inc. for novel RNA-based medicines, to expand its therapeutic reach and accelerate drug discovery. ACADIA's business model centers on identifying promising drug candidates, advancing them through rigorous clinical trials, and successfully bringing them to market to improve the lives of patients suffering from debilitating neurological conditions.